Survodutide
BI 456906 · Boehringer Ingelheim / Zealand Pharma
Glucagon/GLP-1 dual agonist studied in obesity, type 2 diabetes, and liver disease.
Selected study results
SYNCHRONIZE-2Mean body-weight reductionBody weight decreased 13.1% · 76 weeks · Phase 3
Mean body-weight reduction · 76 weeks
Study focus: Weight management with type 2 diabetes
Adults with obesity or overweight and type 2 diabetes · Up to 6.0 mg once weekly vs placebo · Trial N=755 · Efficacy estimand (assumes continued treatment). Results & methods ↗ · Publication ↗
Maximum-dose efficacy-estimand result (“up to”); treatment-regimen estimates include the effects of treatment discontinuation. In SYNCHRONIZE-2, 18% stopped treatment because of gastrointestinal adverse events versus 1.2% with placebo.
SYNCHRONIZE-CVOT · cardiovascular safetyFive-point MACE hazard ratio versus placeboFive-point MACE hazard ratio versus placebo: HR 0.89 · Event-driven trial · Phase 3
Five-point MACE hazard ratio versus placebo · Event-driven trial
Study focus: Cardiovascular / kidney outcomes
HR 0.89 (95% CI 0.67–1.18); p<0.0001 for noninferiority.
Adults with overweight or obesity and established cardiovascular disease, chronic kidney disease or elevated cardiovascular risk · Survodutide 3.6 or 6.0 mg once weekly versus placebo · Trial N=5530 · Treatment-regimen estimand; prespecified noninferiority endpoint. Results & methods ↗ · Publication ↗
The confidence interval includes 1.0: superiority and cardiovascular risk reduction were not established. Five-point MACE includes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, ischemia-related coronary revascularization and heart-failure events. ClinicalTrials.gov has no results posted; the numerical estimate shown comes from the sponsor’s November 9 report.
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
SYNCHRONIZE-2 · HbA1cHbA1c reduction from baselineHbA1c decreased 1.21 percentage points · 76 weeks · Phase 3
HbA1c reduction from baseline · 76 weeks
Study focus: Glycemic control in type 2 diabetes
Adults with obesity or overweight and type 2 diabetes · Up to 6.0 mg once weekly vs placebo · Trial N=755 · Efficacy estimand; baseline HbA1c 7.4%. Results & methods ↗ · Publication ↗
Maximum-dose efficacy-estimand result (“up to”); treatment-regimen estimates include the effects of treatment discontinuation.
SYNCHRONIZE-1Mean body-weight reductionBody weight decreased 13% · 76 weeks · Phase 3
Mean body-weight reduction · 76 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a weight-related complication, without diabetes · 6 mg once weekly vs placebo · Trial N=725 · Treatment-regimen estimand. Results & methods ↗ · Publication ↗
This analysis includes the effects of treatment discontinuation. Adherence-based estimates answer a different question; the 16.6% headline should not be substituted into this comparison.
SYNCHRONIZE-MASLD · primary liver-fat endpointParticipants with ≥30% liver-fat reduction by MRI-PDFFParticipants with ≥30% liver-fat reduction by MRI-PDFF: 68.5% · 48 weeks · Phase 3
Participants with ≥30% liver-fat reduction by MRI-PDFF · 48 weeks
Study focus: Liver outcomes (MASLD / MASH)
Adults with obesity or overweight and at-risk MASLD · 6 mg once weekly vs placebo · Trial N=216 · Treatment-regimen estimand. Results & methods ↗ · Publication ↗
- Same study · body-weight endpointAt 48 weeks, mean body-weight reduction was 8.7% versus 1.4% with placebo (treatment-regimen estimand).
The primary endpoint was a relative reduction in MRI-PDFF liver fat; it is not a liver-histology or approval outcome.
Phase 2 obesity dose-finding studyMean body-weight reductionBody weight decreased 14.9% · 46 weeks · Phase 2
Mean body-weight reduction · 46 weeks
Study focus: Weight management without type 2 diabetes
Adults with overweight or obesity without diabetes · 4.8 mg once weekly vs placebo · Trial N=387 · Planned-treatment analysis. Results & methods ↗
Dose-finding Phase 2 study; this 4.8 mg arm is one within-study comparison.
Phase 2 MASH histology studyParticipants with MASH improvement without fibrosis worseningParticipants with MASH improvement without fibrosis worsening: 62% · 48 weeks · Phase 2
Participants with MASH improvement without fibrosis worsening · 48 weeks
Study focus: Liver outcomes (MASLD / MASH)
Adults with biopsy-confirmed MASH and F1–F3 fibrosis · 4.8 mg once weekly vs placebo · Trial N=293 · Primary histologic endpoint. Results & methods ↗ · Publication ↗
Dose-ranging Phase 2 liver study. Histologic MASH response is distinct from obesity-stage evidence and is not an approval.
Diabetes-focused studies
These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.
Survodutide Phase 2 T2D dose-finding studyHbA1c change from baseline at week 16HbA1c decreased 1.71 percentage points · 16 weeks · Phase 2
HbA1c change from baseline at week 16 · 16 weeks
Study focus: Glycemic control in type 2 diabetes
Adults with type 2 diabetes on metformin · 1.8 mg once weekly vs placebo · Trial N=413 · Adjusted mean change; primary glycemic outcome. Results & methods ↗ · Publication ↗
- Same study · body-weight outcomeAt the highest dose (1.8 mg twice weekly), mean body-weight change was −8.7% versus −5.3% with semaglutide 1.0 mg weekly at week 16.
Dose-finding Phase 2 study; this diabetes population differs from the obesity-only trials.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: SYNCHRONIZE-CVOT met its cardiovascular-safety noninferiority endpoint; results reported November 9, 2026 with a linked Lancet publication. This does not establish cardiovascular superiority.
Next: Further Phase 3 metabolic and liver studies continue; SYNCHRONIZE-T2D evaluates glycemic control in adults with type 2 diabetes.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies5 records
SYNCHRONIZE-1
Weight management without type 2 diabetesAdults with obesity or overweight without type 2 diabetes; 76-week chronic weight-management study. Peer-reviewed results published in 2026.
SYNCHRONIZE-2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes; 76-week Phase 3 study. Peer-reviewed weight and glycemic results published in 2026.
SYNCHRONIZE-HERA
Weight management during or after menopauseRegistered Phase 3 study in women going through or after menopause; not yet recruiting.
SYNCHRONIZE-JP and SYNCHRONIZE-CN
Weight managementRegional obesity studies in Japan and China. The Japan trial (NCT06176365) and China trial (NCT06214741) both have completed registry records.
SYNCHRONIZE-START
Weight managementRegistered open-label, nonrandomized pragmatic Phase 3b study; not yet recruiting.
Phase 2 studies2 records
Survodutide type 2 diabetes dose-finding study
Glycemic control and weight outcomes in type 2 diabetesAdults with type 2 diabetes on metformin; 16-week dose-finding study compared survodutide with placebo and open-label semaglutide. Published results in Diabetologia.
Survodutide obesity dose-finding study
Weight managementAdults with overweight or obesity without diabetes; 46 weeks. At 4.8 mg weekly, mean weight change was −14.9% versus −2.8% with placebo in the planned-treatment analysis.
Related conditions and outcomes
Phase 3 studies5 records
LIVERAGE
Liver outcomes (MASLD / MASH)Adults with MASH and moderate-to-advanced fibrosis, stages F2–F3. Separate global liver-disease program.
LIVERAGE-Cirrhosis
Liver outcomes (MASLD / MASH)Adults with compensated MASH cirrhosis, stage F4. Separate global liver-disease program.
SYNCHRONIZE-CVOT
Cardiovascular outcomesCompleted randomized Phase 3 cardiovascular-safety trial, N=5,530. Noninferiority established; superiority not established. No results posted to the registry; external results reported November 9, 2026.
SYNCHRONIZE-MASLD
Liver outcomes (MASLD / liver fat)Adults with obesity and at-risk MASLD, including noninvasive-test-defined disease or recent biopsy-confirmed MASH. Published 48-week liver-fat and weight results in 2026.
SYNCHRONIZE-T2D
Glycemic control in type 2 diabetesGlycemic-control study in adults with type 2 diabetes receiving diet and physical activity alone or with oral antidiabetic medicines or insulin.
Phase 2 studies2 records
ELEVATE-LIVER
Cardiac structure and function in liver diseaseRegistered Phase 2 study of cardiac structure/function in a liver-disease population; not yet recruiting. Weight is not its primary outcome.
Survodutide MASH and fibrosis study
Liver outcomes (MASLD / MASH)Biopsy-confirmed MASH with F1–F3 fibrosis; 48-week histology study. Published in 2024; this is a liver-disease result, not the obesity stage.
